Niclosamide-BAY2353-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemENiclosamideCat.No.:HY-B0497CASNo.:50-65-7Synonyms:BAY2353分⼦式:C₁₃H₈Cl₂N₂O₄分⼦量:327.12作⽤靶点:STAT;Parasite;Antibiotic作⽤通路:JAK/STATSignaling;StemCell/Wnt;Anti-infection储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMF:5mg/mL(15.28mM;Needultrasonic)DMSO:4.55mg/mL(13.91mM;Needultrasonic)H2O:<0.1mg/mL(ultrasonic;warming;heatto60°C)(insoluble)MassSolvent1mg5mg10mgConcentration制备储备液1mM3.0570mL15.2849mL30.5698mL5mM0.6114mL3.0570mL6.1140mL10mM0.3057mL1.5285mL3.0570mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMF>>40%PEG300>>5%Tween-80>>45%salineSolubility:0.5mg/mL(1.53mM);Suspendedsolution;Needultrasonic2.请依序添加每种溶剂：20%HP-β-CD>>5%CremophorELSolubility:5mg/mL(15.28mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY⽣物活性Niclosamide(BAY2353)⼀种具有⼝服活性的⽤于寄⽣⾍感染研究的抗蠕⾍化合物。NiclosamideSTAT3抑制剂，在HeLa细胞中的IC50为0.25μM。Niclosamide具有抗癌的⽣物活性，并能抑制VeroE6细胞的DNA复制。IC50&TargetSTAT30.25μM(IC50,inHeLacells)体外研究Niclosamide(0.6nM-46µM)treatmentinhibitsadrenocorticalcarcinomacellularproliferationinBD140A,SW-13,andNCI-H295Rcells[3].Niclosamide(0.05-5μM,24h)treatmentinhibitsSTAT3-mediatedluciferasereporteractivityinHeLacells[4].Niclosamide(10μM)treatmentinhibitsvirusreplicationinVeroE6cells[5].CellViabilityAssay[3]CellLine:BD140A,SW-13andNCI-H295RcellsConcentration:0.6nM-46µMIncubationTime:Result:InhibitedcellularproliferationinadrenocorticalcarcinomacelllineswiththeIC50of0.12µM,0.15µM,and0.53µMinBD140A,SW-13,andNCI-H295R,respectively.CellViabilityAssay[4]CellLine:HelacellsConcentration:0.05-5μMIncubationTime:24hoursResult:InhibitedSTAT3-mediatedluciferasereporteractivitywithanIC50of0.25μM.CellViabilityAssay[4]CellLine:VeroE6cells[5]Concentration:10μM2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEIncubationTime:2daysResult:InhibitedthesynthesisofviralantigensofSARS-CoVinVeroE6cells.体内研究Niclosamide(oralgavage;100mg/kg,200mg/kg;onceaweek;8weeks)treatmentinhibitsadrenocorticalcarcinomatumorgrowthinvivo[3].AnimalModel:Nu+/Nu+miceinjectedwithNCI-H295Rcells[3]Dosage:100mg/kg,200mg/kgAdministration:Oralgavage;100mg/kg,200mg/kg;onceaweek;8weeksResult:Showeda60%-80%inhibitionintumorgrowth,ascomparedtothecontrolgroup.户使⽤本产品发表的科研⽂献•CellRes.2022Jun;32(6):513-529.•EmergMicrobesInfect.2022Dec;11(1):483-497.•CellSyst.2018Apr25;6(4):424-443.e7.•AntiviralRes.January2022,105228.•CellDeathDis.2022Feb3;13(2):112.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].PAndrews,etal.Thebiologyandtoxicologyofmolluscicides,Bayluscide.PharmacolTher.1982;19(2):245-95.[2].WeiChen,etal.Niclosamide:Beyondanantihelminthicdrug.CellSignal.2018Jan;41:89-96.[3].KeiSatoh,etal.IdentificationofNiclosamideasaNovelAnticancerAgentforAdrenocorticalCarcinoma.ClinCancerRes.2016Jul15;22(14):3458-66.[4].XiaomeiRen,etal.IdentificationofNiclosamideasaNewSmall-MoleculeInhibitoroftheSTAT3SignalingPathway.ACSMedChemLett.2010Sep7;1(9):454-9.[5].Chang-JerWu,etal.Inhibitionofsevereacuterespiratorysyndromecoronavirusreplicationbyniclosamide.AntimicrobAgentsChemother.2004Jul;48(7):2693-6.McePdfHeightCauti